Comparative Pharmacology
Head-to-head clinical analysis: GILDESS 1 20 versus MICROGESTIN FE 1 5 30.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GILDESS 1 20 versus MICROGESTIN FE 1 5 30.
GILDESS 1/20 vs MICROGESTIN FE 1.5/30
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GILDESS 1/20 is a combination oral contraceptive containing ethinyl estradiol (an estrogen) and gestodene (a progestin). Its primary mechanism is inhibition of ovulation via suppression of gonadotropin-releasing hormone (GnRH), leading to reduced follicle-stimulating hormone (FSH) and luteinizing hormone (LH) secretion. Additionally, it alters cervical mucus (increasing viscosity to impede sperm penetration) and endometrial structure (rendering it unsuitable for implantation).
Combination oral contraceptive: ethinyl estradiol (estrogen) and norethindrone acetate (progestin) suppress gonadotropin (FSH, LH) release, preventing ovulation; increase cervical mucus viscosity, inhibiting sperm penetration; alter endometrial development, reducing implantation likelihood.
One tablet orally daily, each containing 20 mcg ethinyl estradiol and 150 mcg desogestrel.
One tablet (norethindrone acetate 1.5 mg, ethinyl estradiol 30 mcg) orally once daily for 28-day cycles (21 active tablets + 7 ferrous fumarate tablets).
None Documented
None Documented
Ethinylestradiol: terminal half-life ~13-27 hours (mean 17 hours). Gestodene: terminal half-life ~12-15 hours. Steady-state reached within 5-7 days.
Norethindrone: 6-8 hours (terminal); Ethinyl estradiol: 12-18 hours (terminal). Clinical context: Steady-state achieved within 5-7 days; dosing interval suitable for once-daily administration.
Renal (estradiol: ~40-50% as glucuronide and sulfate conjugates; gestodene: ~30-40% as metabolites) and fecal (estradiol: ~20-30%; gestodene: ~30-40%). Less than 1% excreted unchanged.
Norethindrone: 50-60% renal (as metabolites), 20-40% fecal; Ethinyl estradiol: ~40% renal, ~60% fecal (as glucuronide/sulfate conjugates).
Category C
Category C
Oral Contraceptive
Oral Contraceptive